placebo + suvorexant

This is a combination of a placebo and suvorexant. Suvorexant is an orally administered small molecule that acts as a dual orexin receptor antagonist, specifically blocking the orexin 1 (OX1R) and orexin 2 (OX2R) receptors in the brain. By inhibiting these receptors, which are involved in promoting wakefulness, suvorexant reduces arousal and facilitates sleep onset and maintenance. It is primarily indicated for the treatment of insomnia characterized by difficulties with sleep initiation or maintenance. The addition of "placebo" indicates this combination may be used in clinical trial settings to compare active drug effects versus inactive control[1][3][6].